Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Subcutaneous Ianalumab (VAY736) Added to Standard Therapy in Systemic Lupus Erythematosus

The primary objective is to assess whether subcutaneous ianalumab administered at the specified dose achieves superiority over placebo in the proportion of participants attaining the Systemic Lupus Erythematosus Responder Index (SRI‑4) at Week 60 without treatment discontinuation or use of restricted/rescue medications.

Secondary objectives include demonstration of superiority of ianalumab versus placebo for:

• Reduction of moderate or severe BILAG‑2004 flares through Week 60;
• Maintenance of corticosteroid dose ≤5 mg/day (or ≤ baseline dose) between Weeks 36 and 60;
• Achievement of BILAG‑based Composite Lupus Assessment (BICLA) at Week 60;
• Achievement of Lupus Low Disease Activity State (LLDAS) at Week 60;
• Time to first SRI‑4 response from baseline to Week 60;
• SRI‑4 response at Week 60 while maintaining reduced corticosteroid dose;
• Achievement of SRI‑6 response at Week 60;
• Improvement in bodily pain as measured by the SF‑36 at Week 60;
• Evaluation of safety and tolerability of ianalumab;
• Assessment of immunogenicity;
• Characterization of the pharmacokinetic profile.

The trial enrolled 276 participants diagnosed with Systemic Lupus Erythematosus who were aged 12 years or older (with a minimum age of 18 years in regions where minors were not permitted); both male and female individuals were included. All subjects had a confirmed diagnosis according to the 2019 EULAR/ACR classification criteria for at least six months prior to screening, tested positive for antinuclear antibodies (titer ≥1:80) with a typical fluorescence pattern, and exhibited moderate‑to‑severe disease activity as defined by a SLEDAI‑2K score of ≥6 (excluding specific items) and a British Isles Lupus Assessment Group‑2004 level of A in at least one organ system or level B in two or more organ systems. Participants were required to weigh at least 35 kg and to be receiving standard‑of‑care therapy, which could include corticosteroids, antimalarials, or other disease‑modifying antirheumatic drugs. The population represented a broad range of adult and adolescent patients with active disease while adhering to the outlined inclusion criteria.

The study is a randomized, double‑blind, parallel‑group, placebo‑controlled Phase 3 trial evaluating two subcutaneous ianalumab regimens added to standard‑of‑care therapy in participants with Systemic Lupus Erythematosus. After a screening visit to confirm eligibility, participants are randomized 1:1:1 to receive ianalumab 300 mg, an alternative ianalumab dose, or matching placebo administered subcutaneously every four weeks for 60 weeks. Study visits are scheduled at baseline (Week 0) and at Weeks 4, 12, 24, 36, 48, and 60 for efficacy and safety assessments, followed by an end‑of‑study visit at Week 68 for final follow‑up. The primary endpoint is the proportion of participants achieving SRI‑4 at Week 60 without treatment discontinuation or prohibited rescue medication; secondary endpoints include flare rates, corticosteroid‑sparing, composite disease activity scores, patient‑reported outcomes, adverse events, laboratory parameters, anti‑ianalumab antibodies, and serum drug concentrations. Participant involvement lasts approximately 68 weeks from first dose to final follow‑up. Early termination may occur due to major protocol violations, serious adverse events requiring discontinuation, withdrawal of consent, or loss to follow‑up. Recruitment began in March 2023 and the study is planned to conclude in January 2029.

The investigational product, identified as VAY736 and containing the monoclonal antibody ianalumab, is supplied as a solution for injection in a pre‑filled syringe. It is administered by subcutaneous injection at a dose of 300 mg per administration according to the study dosing schedule, with the frequency defined in the protocol.

The control arm receives a matching placebo consisting of a 150 mg/1 mL solution for injection in a pre‑filled syringe, administered subcutaneously with the same schedule as the active comparator.

Background therapy classified as standard‑of‑care includes oral entecavir 0.5 mg daily, provided in the pharmaceutical form PHF00082MIG.

Additional background antiviral agents comprise a fixed‑dose combination tablet of emtricitabine and tenofovir disoproxil, administered orally at a total dose of 300 mg daily (PHF00082MIG).

Tenofovir alafenamide is administered orally at a dose of 25 mg daily, also supplied in the PHF00082MIG form.

A glucocorticoid preparation is included as adjunct therapy, dosed at 50 mg per administration; the route and schedule follow routine clinical practice for the underlying disease.

Drug administration is recorded by study staff at each visit. Compliance with oral agents is monitored through pill counts and patient diaries, while subcutaneous injections are documented in injection logs and verified by site personnel.

Efficacy will be evaluated primarily by the proportion of participants achieving SRI-4 at Week 60. Secondary efficacy assessments include the proportion of participants experiencing no moderate or severe British Isles Lupus Assessment Group (BILAG) flare up to Week 60, maintenance of a reduced corticosteroid dose (predniso(lo)ne ≤5 mg/day or ≤baseline dose) between Week 36 and Week 60, achievement of the BILAG‑based Composite Lupus Assessment at Week 60, attainment of Lupus Low Disease Activity State at Week 60, time to first occurrence of SRI‑4 from baseline to Week 60, combined SRI‑4 response with corticosteroid reduction, achievement of SRI‑6 at Week 60, and SF‑36 bodily pain response at Week 60. Additional safety‑related efficacy parameters comprise the incidence of adverse events and serious adverse events, clinical laboratory measurements, vital signs, anti‑ianalumab antibody incidence and titer, and serum ianalumab concentrations throughout treatment and follow‑up.

Assessments will be performed using validated clinical instruments: the Systemic Lupus Erythematosus Responder Index (SRI‑4 and SRI‑6), BILAG flare criteria, the BILAG‑based Composite Lupus Assessment, Lupus Low Disease Activity State criteria, and the SF‑36 questionnaire for bodily pain. Corticosteroid dosing will be recorded at each study visit to evaluate dose reduction. Laboratory analyses for anti‑ianalumab antibodies and drug concentrations will be conducted at predefined timepoints, including baseline, Week 36, Week 60, and end‑of‑study. Data will be analyzed by calculating response proportions and time‑to‑event metrics, with comparisons between the ianalumab and placebo groups performed using appropriate statistical methods for binary and time‑to‑event outcomes.